<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421718</url>
  </required_header>
  <id_info>
    <org_study_id>SFP LUNG</org_study_id>
    <nct_id>NCT02421718</nct_id>
  </id_info>
  <brief_title>Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation</brief_title>
  <official_title>Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Motive:

      In order to improve the treatment technique, a comprehensive follow-up program is needed to
      obtain all relevant patient, treatment and toxicity data from lung cancer patients.

      Goal:

      To set-up and maintain a database containing treatment results in terms of tumor control,
      side effects, complications and patient-reported quality of life.

      A standard database of patients receiving photon treatment will be created. These data are
      then linked to dose-volume data of radiotherapy, with the aim to build prediction models for
      both tumor control and toxicity after radio (chemo) therapy that can later be used for
      selecting patients for proton treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>Highest during and within 2 weeks after last day of radiation therapy</time_frame>
    <description>esophagitis (Common Terminology Criteria for Adverse Events, version 4.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>Highest within one year after last day of radiation therapy</time_frame>
    <description>esophagitis (Common Terminology Criteria for Adverse Events, version 4.0); pneumonitis (Common Terminology Criteria for Adverse Events, version 4.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 1 year after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 2 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 4 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 5 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumor control</measure>
    <time_frame>at 1 year after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumor control</measure>
    <time_frame>at 2 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional tumor control</measure>
    <time_frame>at 3 years after first day of radiation therapy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>Within 1 week before or after last day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 3 months after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 6 months after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at one year after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 2 years after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 3 years after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 4 years after first day of radiation therapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated symptoms and Quality-of-Life</measure>
    <time_frame>at 5 years after first day of radiation therapy</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <other_name>Chemoradiation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer - Limited
        Disease (SCLC-LD) or thymoma or lungmetastases (treated with stereotactic radiotherapy),
        receiving radiotherapy dose &gt; 40 Gy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with
             stereotactic radiotherapy)

          -  Patients receiving radiotherapy dose &gt; 40 Gy

        Exclusion Criteria:

          -  Failure to comply with any of the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Wijsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Wijsman, MD</last_name>
    <phone>+31503615532</phone>
    <email>r.wijsman@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Wijsman, MD</last_name>
      <phone>+31503615532</phone>
      <email>r.wijsman@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Robin Wijsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>R. Wijsman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acute toxicity</keyword>
  <keyword>Late toxicity</keyword>
  <keyword>Prediction models</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

